Ligand Pharma Guides FY23 EPS Above View, But Revenue Shy Of

WASHINGTON (dpa-AFX) - Ligand Pharmaceuticals Incorporated (LGND) on Tuesday issued revenue and earnings guidance for the fiscal 2023. While revenue guidance is below the Street view, earnings

Related Keywords

Washington , United States , , Ligand Pharmaceuticals Incorporated , Thomson , Reuters , Pharmaceuticals Incorporated , Ligand , Dharma , Uides , Y23 , Above , View , Revenue , Estimates ,